Search results
Start date:
Dec 03, 2025
Severe tricuspid regurgitation (TR) remains an under-recognised and under-treated condition, stressing the importance of timely identification and referral to improve clinical outcomes.In this interactive session, Prof Marianna Adamo (University of Brescia, Brescia, IT) and Prof Volker Rudolph (Heart and Diabetes Center NRW, Bad Oeynhausen, DE) moderate an expert faculty of Prof Marta Sitges …
View more
Added:
1 month ago
Source:
Radcliffe Cardiology
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease associated with a significant burden of recurrent cardiovascular (CV) events. A new post hoc analysis of the ATTRibute-CM trial suggests that acoramidis, an oral transthyretin (TTR) stabiliser, significantly reduces the cumulative burden of these outcomes.¹MethodologyThis exploratory analysis used data from the phase 3,…
View more
Challenges in ATTR Amyloidosis: An Expert Debate
Video Series
Added:
2 months ago
Source:
Radcliffe Cardiology
For patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), the net effect of right ventricular pacing (RVP) has been variable. A new trial suggests that personalising the therapy by electromechanically optimising the atrio-ventricular delay (AVD) can provide a net benefit for symptoms and exercise capacity.¹Right ventricular pacing can reduce the left ventricular outflow tract…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
Cardiovascular magnetic resonance (CMR) with extracellular volume (ECV) mapping can effectively track changes in cardiac amyloid burden in transthyretin amyloid cardiomyopathy (ATTR-CM) and is independently associated with patient outcomes, according to a new prospective study.¹This single-centre prospective study included 189 patients with ATTR-CM. The cohort was divided into an untreated group …
View more
Added:
1 year ago
Explore the cardiovascular breakthroughs shaping AHA 2024!Join renowned experts Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) as they preview the most impactful late-breaking studies poised to make waves at this year’s AHA Conference. Dive into their expert analysis and gain key insights into the studies that are set to drive the future of cardiovascular…
View more
Added:
5 months ago
Stay at the forefront of cardiovascular medicine with our comprehensive video collection from the American Heart Association's Scientific Sessions 2025. Access expert analysis of the most impactful late-breaking trials and featured science shaping clinical practice.Late-Breaker Discussions: Watch Dr Harriette Van Spall break down pivotal clinical trial data and explore its implications for…
View more
Added:
2 months ago
Source:
Radcliffe Cardiology
For patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), the net effect of right ventricular pacing (RVP) has been variable, as it can reduce the left ventricular outflow tract gradient (LVOTg) but may also decrease cardiac output.¹ The EMORI-HCM trial investigated whether electromechanically optimising the atrio-ventricular delay (AVD) could allow RVP to achieve a consistent…
View more
Added:
3 months ago
Source:
Radcliffe Cardiology
An exploratory analysis of the ODYSSEY-HCM trial has shown that mavacamten significantly reduces key cardiac biomarkers in patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM), a condition with no approved therapies.¹ While the main trial did not meet its primary endpoints of improving functional capacity or patient-reported health status, these biomarker findings suggest a…
View more